(Date:12/10/2009)... Dec. 10 Dendreon Corporation (Nasdaq: DNDN ... public offering of 15,000,000 shares of its common stock ... share. Dendreon also granted to the underwriters a ... shares of common stock to cover overallotments, if any. ... 15, 2009, subject to customary closing conditions. ,, J. ...
(Date:12/10/2009)... a division of the National Institutes of Health (NIH), awarded ... its development of a non-invasive, passive diffusion-based treatment for severe, ... ... Salt Lake City, UT (PRWEB) December 10, 2009 -- The ... of Health (NIH), awarded a $2.18 million grant to Aciont ...
(Date:12/10/2009)... YM BioSciences Inc. (NYSE Amex: YMI ; ... that identifies and advances a diverse portfolio of ... today provided an update on the proposed transaction ... Ltd. into YM, details of which were announced ... of Cytopia has unanimously recommended that its shareholders ...
(Date:12/10/2009)... 10 Vivakor, Inc. (OTC Bulletin ... entered into an exclusive, $5 million license ... Inc. ( www.regeneca.com ). The agreement ... a new cutting-edge nutraceutical formulation developed by ... future formulations by Vivakor for Regeneca. Under ...
Breaking Biology Technology:Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3... FORD, Pa., Jan. 28 Endo Pharmaceuticals Inc. (Nasdaq: ... and 2008 full-year financial results on February 27, 2009 ... at 10:30 a.m. ET that day to discuss these ... Officer, Nancy J. Wysenski, Chief Operating Officer and Blaine ...
... Today the Swiss,pharmaceutical group Helsinn announced the ... with headquarters in,Bridgewater, New Jersey, for an undisclosed ... of a US-based R&D and commercial operation represents,attainment ... goals. "We are,thrilled at this very important opportunity ...
... NOVATO, Calif., Jan. 28 BioMarin Pharmaceutical,Inc. (Nasdaq: ... BioMarin, will host a conference call and webcast on,Wednesday, February ... quarter,and full year 2008 financial results. , , ... International Dial-in Number: 617.213.8835, Participant ...
Other Biology Technology:Endo Pharmaceuticals to Announce Fourth Quarter and 2008 Full-Year Financial Results on February 27, 2009 2Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 2Helsinn Announces the Acquisition of Sapphire Therapeutics Inc., USA to Establish Helsinn Therapeutics (US) Inc. 3BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET) 2This antibody detects an ~92 kDa protein corresponding to the apparent molecular mass of the beta subunit of Hypoxia Inducible Factor-1 (HIF-1beta) on Western blots....
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
Complexin-1/2 (FL-134)...
RAW; Collected from 8-12 week old sexually mature mice that are free of common parasites; RAW Collected from 8-12 week old sexually mature mice that are free of common parasites....
Biology Products:Biology NavigationMedical Navigation